Evaluation of the direct and indirect impact on pneumonia hospitalization after almost a decade of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Brazil: Evaluation of 10-valent pneumococcal vaccine on pneumonia hospitalization in Brazil

dc.creatorHammes Varela, Fernanda
dc.creatorCosta, Eduardo
dc.creatorComerlato Scotta, Marcelo
dc.creatorTetelbom Stein, Renato
dc.date2023-03-03
dc.date.accessioned2023-09-01T12:55:56Z
dc.date.available2023-09-01T12:55:56Z
dc.identifierhttps://seer.ufrgs.br/index.php/hcpa/article/view/124378
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8570899
dc.descriptionIntroduction: Pneumococcal pneumonia is a leading cause of severe disease, leading to approximately 2.2 million hospital admissions in 2019 in Brazil. Since 2010, the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine was introduced in Brazil as part of the National Immunization Program (NIP) with free-for-all access, approaching coverage of 91.4% in 2019. Although studies from many countries are available, there is still a need to understand the effect of the vaccine introduction on the incidence of pneumonia hospitalizations in Brazil. Methodology: We accessed data on hospitalization associated with the diagnosis of pneumonia in the population assisted by the Brazilian Public Health system to fit a time series analysis testing the main hypothesis of the influence of vaccination on the trends for the incidence of pneumonia hospitalizations . Results: The post-vaccination period showed a negative trend, reducing 1.75, 0.16, and 0.11 cases per 100,000 inhabitants per month for the groups <1 year, 1-4 year, and 5-9 year, respectively. In age groups larger than 20 years, the post-vaccination period has a positive trend, but not as great as compared trends before the vaccination period. These results point to a protective herd effect in the elderly population nine years after introducing the pneumococcal vaccine in the NIP. Conclusions: The universal vaccination has been shown to reduce hospitalizations associated with pneumonia diagnosis both in the vaccinated and non-vaccinated population in a sustained and progressive manner.en-US
dc.formatapplication/pdf
dc.languagepor
dc.publisherHCPA/FAMED/UFRGSpt-BR
dc.relationhttps://seer.ufrgs.br/index.php/hcpa/article/view/124378/88077
dc.rightsCopyright (c) 2022 Fernanda Hammes Varela, Eduardo Costa, Marcelo Comerlato Scotta, Renato Tetelbom Steinpt-BR
dc.rightshttps://creativecommons.org/licenses/by/4.0pt-BR
dc.sourceClinical & Biomedical Research; Vol. 42 No. 4 (2022): Clinical & Biomedical Researchen-US
dc.sourceClinical and Biomedical Research; v. 42 n. 4 (2022): Clinical & Biomedical Researchpt-BR
dc.source2357-9730
dc.subjectConjugate vaccinept-BR
dc.subjectpneumoniapt-BR
dc.subjectpneumococcal vaccinept-BR
dc.subjectherd immunitpt-BR
dc.subjectPHiD-CVpt-BR
dc.titleEvaluation of the direct and indirect impact on pneumonia hospitalization after almost a decade of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Brazil: Evaluation of 10-valent pneumococcal vaccine on pneumonia hospitalization in Brazilen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Articleen-US
dc.typeAvaliado por Parespt-BR


Este ítem pertenece a la siguiente institución